Two sizeable transactions in oncology — spanning diagnostics and drug development — are underscoring how large healthcare companies are deploying capital across very different parts of the market.
Abbott Laboratories (NYSE:ABT) is set to complete its US$21 billion acquisition of Exact Sciences (NASDAQ:EXAS) on Monday, adding established cancer screening and precision diagnostics assets to its portfolio. And on Friday, Novartis AG (ADR) (NYSE:NVS) announced it has moved to acquire a portfolio of early-stage PI3Kα inhibitor programs, targeting the next wave of breast cancer therapies.
The deals sit at opposite ends of the risk spectrum, but both point to sustained strategic interest in oncology and a continued willingness to pursue growth through acquisition.
Buying scale in diagnostics
Abbott’s acquisition of Exact Sciences is a clear example of the push into established, revenue-generating platforms.
The deal brings a portfolio of cancer screening and precision diagnostics into Abbott’s diagnostics division, including colorectal cancer test Cologuard and breast cancer assay Oncotype DX. These products are already widely used and generate significant revenue.
Abbott expects the transaction to contribute around US$3 billion in incremental sales in 2026, while expanding its position in a US cancer screening and precision oncology diagnostics market it estimates at about US$60 billion.
Beyond the current portfolio, Exact Sciences also adds a pipeline of multi-cancer early detection blood tests and molecular residual disease (MRD) diagnostics, extending Abbott’s reach across the cancer care continuum — from screening through to post-treatment monitoring.
The strategic focus is on scale and growth in diagnostics, a segment that continues to benefit from increasing demand for earlier detection and more personalised approaches to treatment.
Buying differentiation in the pipeline
Novartis is taking a more forward-looking approach, targeting early-stage assets with the potential to improve on existing therapies.
The company has agreed to acquire PI3Kα inhibitor programs from Synnovation Therapeutics for US$2 billion up front, with up to US$1 billion in additional milestone payments.
The lead candidate, SNV4818, is designed to selectively target mutated PI3Kα enzymes in cancer cells while sparing the normal form found in healthy tissue.
That selectivity is intended to address a known limitation of earlier-generation drugs in this class, which inhibit both mutant and wild-type PI3Kα and can lead to tolerability issues. By focusing only on the mutated enzyme, the next generation of inhibitors aims to improve safety profiles and support more consistent dosing, including in combination therapies.
The program remains in early clinical development, and its eventual role in treatment pathways will depend on ongoing trial results. But the acquisition reflects continued interest in refining established oncology targets rather than moving entirely into new mechanisms.
A market testing different approaches
The contrast between the two deals points to the range of strategies currently in play across the sector, rather than a single direction.
Diagnostics and disease management platforms continue to offer visibility on revenue and clearer pathways to scale, particularly as healthcare systems place greater emphasis on early detection and monitoring.
At the same time, early-stage drug development is still attracting capital where assets show a clear point of differentiation, even within well-established therapeutic classes.
Oncology sits at the centre of both transactions, but the approaches to growth differ.
What it means for investors
For investors, the deals reinforce that large-cap healthcare companies remain active in pursuing external growth, with oncology continuing to attract a significant share of that capital.
Abbott’s acquisition highlights the appeal of established, revenue-generating platforms, particularly in diagnostics and screening. Novartis’ move points to continued interest in earlier-stage assets where there is potential to improve on existing therapies.
The deals reflect different timelines and risk profiles — but both show that strategic buyers are still willing to deploy capital where the rationale is clear.